<i>pat-2</i> mutants contain more apoptotic cells during mid-embryogenesis than the wild-type.

a<p>The number of cell corpses in each genotype was scored at the indicated embryonic stage.</p>b<p>Embryos that showed normal embryogenesis were scored as nonPat and those paralyzed at the 2-fold stage were scored as Pat.</p>c<p>Homozygous progeny of <i>unc-79(e1068) pat-2(st567)/dpy-17(e164)</i> heterozygous mothers.</p>d<p>Non-transgenic progeny of <i>unc-79(e1068) pat-2(st567); Ex[P_pat-2pat-2::gfp]</i> mothers.</p>e<p>Non-transgenic progeny of <i>unc-79(e1068) pat-2(st567); ced-3(n717); Ex[P_pat-2pat-2::gfp]</i> mothers.</p>f<p>Homozygous progeny of <i>pat-3(st564)/qC1 dpy-19(e1259) glp-1(q339)</i> heterozygous mothers. <i>pat-2</i>, <i>ina-1</i>, and <i>pat-3</i> single mutants were compared to the wild-type (^**<i>p</i><0.001) and double mutants were compared to the corresponding single mutants (^#<i>p</i><0.05 and ^##<i>p</i><0.001) at each stage. All comparisons were performed using the unpaired t test. The cell corpse numbers of homozygous <i>pat-2(st567)^d</i> embryos treated with <i>pat-2</i> RNAi are not distinguishable from those of <i>pat-2(st567)^d</i> or <i>pat-2</i>(RNAi) embryos at the same stage. Data are presented as the mean ± standard deviation (SD) for >15 embryos per stage.